Search clinical trials for: KD019

Total 17 results

NYU Langone Health

Withdrawn

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

Stomach Cancer | Esophageal Cancer

United States
Roswell Park Cancer Institute

Completed

Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer

Lung Cancer

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Completed

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Cancer

United States
Yale University

Completed

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

Rectal Cancer

United States
Kadmon Corporation, LLC

Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Polycystic Kidney, Autosomal Recessive

United States
Kadmon Corporation, LLC

Completed

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Glioblastoma | Brain Tumor | Recurrent Glioblastoma

United States
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kadmon, a Sanofi Company

Completed

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Kadmon Corporation, LLC

Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

HER-2 Positive Breast Cancer | Metastatic Malignant Neoplasm to Brain

United States
Kadmon Corporation, LLC

Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Non-Small Cell Lung Cancer | Brain Metastases | Leptomeningeal Metastases

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Edward Chu, MD
Kadmon Corporation, LLC

Completed

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma

United States

3

Subscribe